Achieve a better understanding of biological safety evaluation and answer questions related to what you should be doing as a device manufacturer to comply with FDA guidance while keeping your overall program costs manageable. 






This white paper proposes a test method that addresses FDA expectations, practical considerations, and inherent limitations of the canine thrombogenicity test.

By Christopher Parker, M.S., M.B.A.


Amid efforts at harmonization, important differences exist between U.S./FDA/ISO and Ministry of Health, Labour, and Welfare (Japan) medical device biocompatibility requirements.

By Laxman Desai, D.Sc. and Laurence Lister

Don't see what you are looking for? Submit the form below.